Compare · CLDX vs TKNO
CLDX vs TKNO
Side-by-side comparison of Celldex Therapeutics Inc. (CLDX) and Alpha Teknova Inc. (TKNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLDX and TKNO operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- CLDX is the larger of the two at $2.26B, about 4.4x TKNO ($516.1M).
- CLDX has been more active in the news (6 items in the past 4 weeks vs 3 for TKNO).
- CLDX has more recent analyst coverage (22 ratings vs 10 for TKNO).
- Company
- Celldex Therapeutics Inc.
- Alpha Teknova Inc.
- Price
- -
- -
- Market cap
- $2.26B
- $516.1M
- 1M return
- +4.97%
- -
- 1Y return
- +11.11%
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 6
- 3
- Recent ratings
- 22
- 10
Celldex Therapeutics Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Latest CLDX
- Amendment: SEC Form SCHEDULE 13G/A filed by Celldex Therapeutics Inc.
- SEC Form S-3ASR filed by Celldex Therapeutics Inc.
- SEC Form 10-Q filed by Celldex Therapeutics Inc.
- Celldex Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Celldex Reports Third Quarter Financial Results and Provides Corporate Update
- Celldex to Present at Upcoming Investor Conferences
- Amendment: SEC Form SCHEDULE 13G/A filed by Celldex Therapeutics Inc.
- H.C. Wainwright reiterated coverage on Celldex Therapeutics with a new price target
- Celldex Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
Latest TKNO
- SEC Form 10-Q filed by Alpha Teknova Inc.
- Alpha Teknova Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Teknova Reports Third Quarter 2026 Financial Results
- Teknova to Report Third Quarter 2026 Financial Results on November 4, 2026
- SEC Form 8-K filed by Alpha Teknova Inc.
- SEC Form 424B5 filed by Alpha Teknova Inc.
- Teknova Announces Pricing of $40 Million Public Offering of Common Stock
- SEC Form 424B5 filed by Alpha Teknova Inc.
- Teknova Announces Proposed Public Offering of Common Stock
- Teknova Announces Preliminary Third Quarter Financial Results